The transformative potential of large-volume subcutaneous drug delivery: a discussion of current capabilities and future prospects for pharmaceutical manufacturers

Abstract This paper explores and discusses the current state and future prospects of large-volume (> 2.0 mL) subcutaneous drug delivery (LVSC), with a focus on its transformative potential for pharmaceutical manufacturing and drug delivery device development. Referring to the success of subcutaneous immunoglobulin (SCIg) therapy, the paper examines its role as a leading example for LVSC drug administration. The discussion extends to other potential drugs transitioning from intravenous (IV) to subcutaneous (SC) delivery. Currently published literature is discussed in this paper that shows key benefits of LVSC drug delivery, such as improved patient convenience, better treatment adherence, and higher cost-effectiveness. The paper further emphasizes how LVSC drug delivery can enhance patient outcomes by enabling self-administration, reducing hospital visits, and optimizing the overall treatment process. As the technique evolves, the opportunities for innovation in drug delivery systems and manufacturing processes are significant, marking a shift towards more patient-centric and efficient therapeutic options in the healthcare industry.